Mabqi leverages on its extensive antibody discovery expertise and cutting-edge platform to propose a pipeline of drug candidates for high, unmet clinical needs.
We focus our discovery engine on finding functional targeted therapies with outstanding characteristics including superior developability profiles, pH sensitivity, and/or binding to exclusive targets such as GPCR or ion channels.
Mabqi, in collaboration with SATT Nord has discovered and characterized a first-in-class human anti-TRPV6 antibody with unique antitumoral properties and high clinical potential.
Comprehensive in vitro and in vivo preclinical studies have demonstrated the safety, efficacy, and clinical relevance of our lead bispecific , positioning it as a promising new candidate for the treatment of solid tumors such as metastatic prostate cancer, sarcoma and ovarian and pancreatic cancers. Other indications are under investigation.
As a first-in-class therapeutic, this innovative anti-TRPV6 drug candidate is well-positioned for accelerated clinical development.
Latest in vitro and in vivo results were presented during major scientific congresses such as American Association for Cancer Research (AACR) 2025 & 2026. First-in-class pan-cancer drug candidate targeting an ion channel, TRPV6, as a new therapeutic agent in oncology.
An oral presentation will be given during the Ion Channel-Targeted Drug Development Summit in September 2026.
Latest publications available here.
In 2025, Mabqi secures non-dilutive funding of €5 million as part of the France 2030 program to advance this lead antibody candidate into clinical development. More information in the press release.
MQI-181 is an innovative tumor-selective antibody combined to an optimised linker/payload. The drug candidate has been designed to actively overcome clinical limitations of current therapies on the market.
MQI-181 demonstrates superior efficacy to SOC in lymphoma and increased therapeutic window.
Latest preclinical results were presented in international congresses:
Preclinical data package is available. The program is currently open for partnering opportunities.
The drug candidate was developed in partnership with an expert in ADC technologies. It has shown an excellent safety profile and robust antitumor activity, including complete tumor regression across various solid tumor models.
The drug candidate is progressing toward clinical evaluation in prostate cancer.
In 2026, the company successfully out-licensed the drug candidate. Access the full press release here.
The company has established a Medical Advisory Board to enhance its ability to identify and select innovative targets. This board comprises international experts in clinical medicine, pharmacology, and pharmaceutical development. The primary purpose of this advisory board is to provide strategic guidance on future product positioning.
Our oncology programs, focused on our lead candidates, are open for collaboration through partnering or out-licensing agreements.
We are committed to pushing the boundaries of immunotherapy by combining state-of-the-art technologies with groundbreaking concepts, aiming to deliver safer and more potent therapeutic solutions.
Furthermore, we are also open to explore partnership opportunities involving innovative targets and mechanisms of action that could be enhanced by our cutting-edge technology platform.
